Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Diffuse leukoencephalopathy with spheroids presenting as primary progressive aphasia
Oboudiyat, Carly, Bigio, Eileen H. , Bonakdarpour, Borna , Baker, Matt , Rademakers, Rosa , Weıntraub, Sandra , Mesulam, M.‐Marsel, Baker, Matt C

Neurology | July 22, 2015 | Volume: 85 | Issue: 7 | Pages: 652-653

10.1212/wnl.0000000000001851 | PMID 26203093 Get It

Frequency Importance Functions in Quiet and Noise for Adults With Cochlear Implants
Sladen, Douglas P. , Ricketts, Todd A.

American Journal of Audiology | July 22, 2015 | Volume: 24 | Issue: 4 | Pages: 477-486

10.1044/2015_aja-15-0023 | PMID 26650018 Get It

PurposeSeveral studies have been devoted to understanding the frequency information available to adult users of cochlear implants when listening in quiet. The objective of this study was to construct frequency importance functions for a group of adults with cochlear implants and a group of adults with normal hearing both in quiet and in a +10 dB signal-to-noise ratio.MethodTwo groups of adults, 1 with cochlear implants and 1 with normal hearing, were asked to identify nonsense syllables in quiet and in the presence of 6-talker babble while “holes” were systematically created in the speech spectrum. Frequency importance functions were constructed.ResultsResults showed that adults with normal hearing placed greater weight on bands 1, 3, and 4 than on bands 2, 5, and 6, whereas adults with cochlear implants placed equal weight on all bands. The frequency importance functions for each group did not differ between listening in quiet and listening in noise.ConclusionsAdults with cochlear implants assign perceptual weight toward different frequency bands, though the weight assignment does not differ between quiet and noisy conditions. Generalizing these results to the broader population of adults with implants is constrained by a small sample size.
Melatonin as a preventive and curative therapy against pulmonary hypertension
Maarman, Gerald J. , Thienemann, Friedrich , Blauwet, Lori A., Butrous, Ghazwan , Davies, Neil H. , Lecour, Sandrine , Blauwet, Lori, Blackhurst, Dee , Sliwa, Karen

Journal of Pineal Research | July 22, 2015 | Volume: 59 | Issue: 3 | Pages: 343-353

10.1111/jpi.12263 | PMID 26201290 Get It

AbstractPulmonary hypertension (PH) is characterized by elevated pulmonary arterial pressure, which leads to right ventricular (RV) hypertrophy and failure. The pathophysiological mechanisms of PH remain unclear but oxidative stress is believed to contribute to RV dysfunction. Melatonin is a powerful antioxidant and is cardioprotective against ischemia–reperfusion injury and hypertension. Therefore, we hypothesized that a chronic treatment with melatonin, given as a curative or preventive therapy, may confer cardiovascular benefits in PH. PH was induced in Long Evans rats (n ≥ 6 per group), with a single subcutaneous injection of monocrotaline (MCT, 80 mg/kg). Melatonin was given daily in the drinking water, with the treatment starting either on the day of the injection of MCT (dose testing: melatonin 75 ng/L and 6 mg/kg), 14 days after the injection of MCT (curative treatment: 6 mg/kg), or 5 days before the injection (preventive treatment: 6 mg/kg). The development of PH was assessed by measuring RV hypertrophy, RV function, cardiac interstitial fibrosis, and plasma oxidative stress. Compared with controls, MCT‐treated rats displayed RV hypertrophy and dysfunction, increased interstitial fibrosis, and elevated plasma oxidative stress. A chronic melatonin treatment (75 ng/L or 6 mg/kg) reduced RV hypertrophy, improved RV function and reduced plasma oxidative stress. Curative and preventive treatment improved RV functional and plasma oxidative stress parameters and reduced cardiac interstitial fibrosis. Our data demonstrate that melatonin confers cardioprotection in this model of PH. As melatonin is an inexpensive and safe drug, we propose that clinical investigation of the effects of melatonin on RV function in patients with PH should be considered.
Autosomal Recessive Bestrophinopathy Is Not Associated With the Loss of Bestrophin-1 Anion Channel Function in a Patient With a NovelBEST1Mutation
Johnson, Adiv A. , Bachman, Lori A. , Gilles, Benjamin, Cross, Samuel D., Stelzig, Kimberly E. , Resch, Zachary T., Marmorstein, Lihua Y., Pulido, José S. , Marmorstein, Alan D. , Gilles, Benjamin J, Stelzig, Kimberly E. , Marmorstein, Alan D

Investigative Opthalmology & Visual Science | July 22, 2015 | Volume: 56 | Issue: 8 | Pages: 4619

10.1167/iovs.15-16910 | PMID 26200502 Get It

Cardio-Oncology: An Ongoing Evolution
Petek, Bradley J. , Greenman, Chris , Herrmann, Joerg , Ewer, Michael S. , Jones, Robin L. , Jones, Robin L

Future Oncology | July 22, 2015 | Volume: 11 | Issue: 14 | Pages: 2059-2066

10.2217/fon.15.89 | PMID 26198836 Get It

Should Vascular Effects of Newer Treatments be Addressed More Completely?
Yang, Eric H. , Herrmann, Joerg , Watson, Karol E. , Yang, Eric

Future Oncology | July 22, 2015 | Volume: 11 | Issue: 14 | Pages: 1995-1998

10.2217/fon.15.119 | PMID 26198824 Get It

Should the ‘Echo Guidelines’ be Followed in Cancer Patients?
Herrmann, Joerg , Yang, Eric H. , Yang, Eric

Future Oncology | July 22, 2015 | Volume: 11 | Issue: 14 | Pages: 2021-2025

10.2217/fon.15.109 | PMID 26198830 Get It

Mapping and Ablation of Rotors: Exploring New Frontiers in Treatment of Ventricular Fibrillation
Killu, Ammar M. , Mulpuru, Siva K.

Journal of Cardiovascular Electrophysiology | July 22, 2015 | Volume: 26 | Issue: 10 | Pages: 1127-1129

10.1111/jce.12760 | PMID 26202001 Get It

Early Hypoparathyroidism Reversibility with Treatment of Riedel's Thyroiditis
Stan, Marius N. , Haglind, Elizabeth G., Drake, Matthew T. , Haglind, Elizabeth, Stan, Marius N

Thyroid | July 22, 2015 | Volume: 25 | Issue: 9 | Pages: 1055-1059

10.1089/thy.2015.0212 | PMID 26200816 Get It

Long‐term outcomes for newly‐diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
Voorhees, Peter M. , Orlowski, Robert Z. , Mulkey, Flora , Geyer, Susan, Sanford, Ben L. , Bennett, Elizabeth , Chanan‐Khan, Asher , Bloomfield, Clara D. , Larson, Richard A. , Chanan-Khan, Asher A., Orlowski, Robert Z. , Watson, Peter J. , Larson, Richard A

British Journal of Haematology | July 22, 2015 | Volume: 171 | Issue: 3 | Pages: 373-377

10.1111/bjh.13592 | PMID 26202857 Get It

SummaryLong‐term outcomes and updated clinical efficacy and safety data were evaluated for newly‐diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near‐complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment‐related ≥Grade 3 non‐haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.